Application of Laser Microdissection and Reverse-Phase Protein Microarrays to the Molecular Profiling of Cancer Signal Pathway Networks in the Tissue Microenvironment

Clinics in Laboratory Medicine

Volumn 29, Issue 1, 2009, Pages 1-13

  Espina, Virginia ^a   Wulfkuhle, Julia ^a   Liotta, Lance A ^a  

^a GEORGE MASON UNIVERSITY   (United States)

Author keywords

Cancer; Laser capture microdissection; Microenvironment; Molecular profiling; Proteomics; Reverse phase protein microarray

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PHOSPHOPROTEIN; PROTEIN; TRASTUZUMAB;

CANCER COMBINATION CHEMOTHERAPY; CANCER TISSUE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DNA FINGERPRINTING; HUMAN; HUMAN TISSUE; LASER MICRODISSECTION; LUNG NON SMALL CELL CANCER; MICROENVIRONMENT; MOLECULAR RECOGNITION; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION; PROTEOMICS; REVERSE PHASE ARRAY; REVIEW; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY;

HUMANS; LASERS; MICRODISSECTION; NEOPLASMS; PROTEIN ARRAY ANALYSIS; PROTEOMICS; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS;

EID: 64649085620     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2009.03.001     Document Type: Review

References (35)

1. Emmert-Buck M.R., Bonner R.F., Smith P.D., et al. Laser capture microdissection. Science 274 (1996) 998-1001
2. Ma X.J., Salunga R., Tuggle J.T., et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A 100 (2003) 5974-5979
3. Espina V., Wulfkuhle J.D., Calvert V.S., et al. Laser capture microdissection. Nat Protoc 1 2 (2006) 586-603
4. van de Vijver M.J., He Y.D., van't Veer L.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347 (2002) 1999-2009
5. Bullinger L., Döhner K., Bair E., et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 350 (2004) 1605-1616
6. Calin G.A., and Croce C.M. MicroRNA signatures in human cancers. Nat Rev Cancer 6 11 (2006) 857-866
7. Petricoin III E.F., Bichsel V.E., Calvert V.S., et al. Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. J Clin Oncol 23 (2005) 3614-3621
8. Yokoyama N., and Malbon C.C. Phosphoprotein phosphatase-2A docks to dishevelled and counterregulates Wnt3a/β-catenin signaling. Published online 2007 October 25. J Mol Signal 2 (2007) 12 10.1186/1750-2187-2-12
9. Bain J., Plater L., Elliott M., et al. The selectivity of protein kinase inhibitors: a further update. Biochem J 408 Pt 3 (2007) 297-315
10. Espina V., Edmiston K.H., Heiby M., et al. A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics 7 10 (2008) 1998-2018
11. Wulfkuhle J.D., Speer R., Pierobon M., et al. Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res 7 (2008) 1508-1517
12. Sreekumar A., Nyati M.K., Varambally S., et al. Profiling of cancer cells using protein microarrays: discovery of novel radiation-regulated proteins. Cancer Res 61 (2001) 7585-7593
13. LaBaer J., and Ramachandran N. Protein microarrays as tools for functional proteomics. Curr Opin Chem Biol 9 (2005) 14-19
14. Robinson W.H. Antigen arrays for antibody profiling. Curr Opin Chem Biol 10 (2006) 67-72
15. Paweletz C.P., Charboneau L., Bichsel V.E., et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20 (2001) 1981-1989
16. Gulmann C., Espina V., Petricoin III E.F., et al. Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma. Clin Cancer Res 11 (2005) 5847-5855
17. Sheehan K.M., Calvert V.S., Kay K.W., et al. Use of reverse-phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics 4 (2005) 346-355
18. Zha H., Raffeld M., Charboneau L., et al. Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray. Lab Invest 84 (2004) 235-244
19. Petricoin III E.F., Espina V., Araujo R.P., et al. Phosphoprotein pathway mapping: akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res 67 7 (2007) 3431-3440
20. Wulfkuhle J.D., Edmiston K.H., Liotta L.A., et al. Technology insight: pharmacoproteomics for cancer-promises of patient-tailored medicine using protein microarrays. Nat Clin Pract Oncol 3 (2006) 256-268
21. VanMeter A.J., Rodriguez A.S., Bowman E.D., et al. Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGFR) phosphorylation events associated with mutated EGFR compared with wild type. Mol Cell Proteomics 7 10 (2008) 1902-1924
22. Nishizuka S., Charboneau L., Young L., et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A 100 (2003) 14229-14234
23. Grote T., Siwak D.R., Fritsche H.A., et al. Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: accurate detection of CA19-9 levels in pancreatic cancer. Proteomics 8 15 (2008) 3051-3060
24. Araujo R.P., Petricoin E.F., and Liotta L.A. A mathematical model of combination therapy using the EGFR signaling network. Biosystems 80 (2005) 57-69
25. Araujo R.P., Doran C., Liotta L.A., et al. Network-targeted combination therapy: a new concept in cancer treatment. Drug Discov Today 1 (2004) 425-433
26. Arteaga C.L., and Baselga J. Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice. Clin Cancer Res 9 (2003) 1579-1589
27. Gasparini G., and Gion M. Molecular-targeted anticancer therapy: challenges related to study design and choice of proper endpoints. Cancer J Sci Am 6 (2000) 117-131
28. Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol 23 (2005) 3235-3242
29. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
30. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
31. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21 (2003) 2237-2246
32. Kris M.G., Natale R.B., Herbst R.S., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. A randomized trial. JAMA 290 (2003) 2149-2158
33. Wu S.L., Kim J., Bandle R.W., et al. Dynamic profiling of the post-translational modifications and interaction partners of epidermal growth factor receptor signaling after stimulation by epidermal growth factor using Extended Range Proteomic Analysis (ERPA). Mol Cell Proteomics 5 (2006) 1610-1627
34. Oksvold M.P., Thien C.B., Widerberg J., et al. Serine mutations that abrogate ligand-induced ubiquitination and internalization of the EGF receptor do not affect c-Cbl association with the receptor. Oncogene 22 (2003) 8509-8518
35. Hynes N.E., and Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5 (2005) 341-354